Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
Lantern Pharma Inc. (LTRN), a Delaware corporation, filed this Current Report on Form 8-K on March 30, 2026. The filing announces the upcoming release of financial results for the fiscal year and fourth quarter ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release (Exhibit 99.1) and presentation (Exhibit 99.2) referenced in the filing but are not detailed in the 8-K body text.
Material Changes
No material changes or comparative financial data are disclosed in the text of this Form 8-K. The document serves solely as a notification of the results announcement.
Guidance, Outlook, and Management Commentary
Management will discuss financial and operating results during a conference call and live webinar on March 30, 2026. A presentation to assist with these discussions is furnished as Exhibit 99.2. The filing explicitly states that the information in the press release and presentation is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section unless expressly incorporated by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net income, and cash flow figures for the year ended December 31, 2025.
- Examine Exhibit 99.2 (Presentation) for management's outlook, guidance, and strategic commentary.
- Verify the timing and access details for the conference call and live webinar mentioned in Item 7.01.
- Confirm the legal status of the disclosed information, noting the disclaimer regarding Section 18 liabilities.